Table 2.
Inverse associations between number of copies of rs174564 minor allele (G) and serum lipids.
| Type | Biochemical | GWAS p value | Effect size | n |
|---|---|---|---|---|
| n-6 Endocannabinoid | 2-Arachidonoylglycerol (20:4) | 2.20 × 10–10 | − 0.25 | 1943 |
| n-6 LC-PUFA | Arachidonate (ARA; 20:4n6) | 3.55 × 10–51 | − 0.53 | 1958 |
| n-6 LC-PUFA | Adrenate (ADA, 22:4n6) | 5.59 × 10–11 | − 0.18 | 1958 |
| n-3 LC-PUFA | Eicosapentaenoate (EPA; 20:5n3) | 6.06 × 10–09 | − 0.18 | 1959 |
| n-6 LC-PUFA-containing lyso-PL | 1-Arachidonoyl-2-lyso-GPC (20:4n6) | 2.72 × 10–73 | − 0.64 | 1956 |
| n-6 LC-PUFA-containing lyso-PL | 1-Lyso-2-arachidonoyl-GPC (20:4) | 8.21 × 10–56 | − 0.57 | 1953 |
| n-6 LC-PUFA-containing lyso-PL | 1-Lyso-2-arachidonoyl-GPE (20:4) | 4.85 × 10–14 | − 0.32 | 1924 |
| n-6 LC-PUFA-containing lyso-PL | 1-Adrenoyl-2-lyso-GPC (22:4) | 6.35 × 10–13 | − 0.28 | 1956 |
| n-6 LC-PUFA-containing lyso-PL | 1-Arachidonoyl-2-lyso-GPI (20:4) | 1.68 × 10–09 | − 0.22 | 1958 |
| n-3 LC-PUFA-containing lyso-PL | 1-Eicosapentaenoyl-2-lyso-GPC (20:5) | 2.66 × 10–10 | − 0.22 | 1957 |
| n-3 LC-PUFA-containing lyso-PL | 1-Docosapentaenoyl-2-lyso-GPC (22:5n3) | 2.93 × 10–10 | − 0.22 | 1958 |
| n-6 LC-PUFA-containing PL | 1-Stearoyl-2-arachidonoyl-GPC (18:0/20:4) | 3.52 × 10–91 | − 0.71 | 1957 |
| n-6 LC-PUFA-containing PL | 1-Palmitoyl-2-arachidonoyl-GPC (16:0/20:4) | 8.05 × 10–72 | − 0.64 | 1959 |
| n-6 or n-3 LC-PUFA-containing PL | Phosphatidylcholine (16:0/22:5n3, 18:1/20:4) | 1.15 × 10–46 | − 0.54 | |
| n-6 LC-PUFA-containing PL | 1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) | 3.78 × 10–48 | − 0.50 | 1911 |
| n-6 LC-PUFA-containing PL | 1-(1-Enyl-stearoyl)-2-arachidonoyl-GPC (P-18:0/20:4) | 3.90 × 10–43 | − 0.47 | 1953 |
| n-9 LC-PUFA-containing PL | 1-Stearoyl-2-meadoyl-GPC (18:0/20:3n9) | 8.30 × 10–28 | − 0.41 | 1958 |
| n-6 LC-PUFA-containing PL | 1-Linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) | 4.10 × 10–29 | − 0.40 | 1955 |
| n-6 LC-PUFA-containing PL | 1-Palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n6) | 1.79 × 10–10 | − 0.38 | 1957 |
| n-9 LC-PUFA-containing PL | 1-Palmitoyl-2-meadoyl-GPC (16:0/20:3n9) | 1.14 × 10–20 | − 0.37 | 1946 |
| n-6 or n-3 LC-PUFA-containing PL | Phosphatidylcholine (18:0/20:5n3, 16:0/22:5n6) | 8.58 × 10–21 | − 0.33 | |
| n-6 LC-PUFA-containing PL | 1-(1-Enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) | 2.91 × 10–19 | − 0.32 | 1959 |
| n-6 LC-PUFA-containing PL | 1-Stearoyl-2-arachidonoyl-GPI (18:0/20:4) | 4.19 × 10–17 | − 0.32 | 1956 |
| n-6 LC-PUFA-containing PL | 1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4) | 7.73 × 10–15 | − 0.29 | 1958 |
| n-3 LC-PUFA-containing PL | 1-Stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) | 1.02 × 10–14 | − 0.29 | 1956 |
| n-6 LC-PUFA-containing PL | 1-Stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6) | 4.26 × 10–10 | − 0.24 | 1958 |
| n-3 LC-PUFA-containing PL | 1-Oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) | 8.51 × 10–11 | − 0.23 | 1938 |
| n-3 LC-PUFA-containing PL | 1-Palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) | 3.51 × 10–10 | − 0.22 | 1959 |
These lipid species are all downstream from the FADS1 enzyme step.